Tags

Type your tag names separated by a space and hit enter

A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
Clin Neurol Neurosurg. 2006 Dec; 108(8):726-32.CN

Abstract

OBJECTIVES

Although levodopa (LD) is the gold standard therapy for symptomatic treatment of Parkinson's disease (PD), the chronic use of LD leads to the development of motor complications in almost all patients.

PATIENTS AND METHODS

We assessed the presence and risk factors for motor complications in PD patients on LD therapy. We examined 555 PD patients on LD for the presence or absence of wearing-off (WO+/-) and dyskinesia (DK+/-).

RESULTS

WO was present in 46.3%, and DK in 30.1% of patients. The mean age at onset of symptoms were earlier in WO(+)/DK(+) groups (p<0.001). The duration of PD was longer in WO(+)/DK(+) groups (p<0.001). The time between the first symptom and the occurrence of WO/DK, or LD initiation were not significantly different. The initial LD dose was significantly higher in WO(+) compared to WO(-) (300.1mg/d versus 232.5mg/d, p<0.001), and DK(+) compared to DK(-) groups (291.4 mg/d versus 251.9 mg/d, p=0.001). The time until dopamine agonist (DA) initiation was longer in WO(+)/DK(+) groups (p<0.001). WO (p<0.001) and DK (p=0.002) were more common in patients with H&Y stages 3+4. UPDRS scores were higher in WO(+) and DK(+) patients (p<0.001 and p=0.027).

CONCLUSION

Our study showed that the development of motor complications was associated with early onset PD, longer disease duration, advanced disease, higher initial LD dose, longer LD use, and late DA initiation, but not with the timing of LD initiation.

Authors+Show Affiliations

Department of Neurology, University of Istanbul, Cerrahpaşa Faculty of Medicine, Istanbul 34098, Turkey.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16564615

Citation

Benbir, Gülçin, et al. "A Hospital-based Study: Risk Factors in Development of Motor Complications in 555 Parkinson's Patients On Levodopa Therapy." Clinical Neurology and Neurosurgery, vol. 108, no. 8, 2006, pp. 726-32.
Benbir G, Ozekmekçi S, Apaydin H, et al. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy. Clin Neurol Neurosurg. 2006;108(8):726-32.
Benbir, G., Ozekmekçi, S., Apaydin, H., Delil, S., & Erginöz, E. (2006). A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy. Clinical Neurology and Neurosurgery, 108(8), 726-32.
Benbir G, et al. A Hospital-based Study: Risk Factors in Development of Motor Complications in 555 Parkinson's Patients On Levodopa Therapy. Clin Neurol Neurosurg. 2006;108(8):726-32. PubMed PMID: 16564615.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy. AU - Benbir,Gülçin, AU - Ozekmekçi,Sibel, AU - Apaydin,Hülya, AU - Delil,Sakir, AU - Erginöz,Ethem, Y1 - 2006/03/27/ PY - 2005/09/16/received PY - 2006/02/05/revised PY - 2006/02/12/accepted PY - 2006/3/28/pubmed PY - 2007/2/13/medline PY - 2006/3/28/entrez SP - 726 EP - 32 JF - Clinical neurology and neurosurgery JO - Clin Neurol Neurosurg VL - 108 IS - 8 N2 - OBJECTIVES: Although levodopa (LD) is the gold standard therapy for symptomatic treatment of Parkinson's disease (PD), the chronic use of LD leads to the development of motor complications in almost all patients. PATIENTS AND METHODS: We assessed the presence and risk factors for motor complications in PD patients on LD therapy. We examined 555 PD patients on LD for the presence or absence of wearing-off (WO+/-) and dyskinesia (DK+/-). RESULTS: WO was present in 46.3%, and DK in 30.1% of patients. The mean age at onset of symptoms were earlier in WO(+)/DK(+) groups (p<0.001). The duration of PD was longer in WO(+)/DK(+) groups (p<0.001). The time between the first symptom and the occurrence of WO/DK, or LD initiation were not significantly different. The initial LD dose was significantly higher in WO(+) compared to WO(-) (300.1mg/d versus 232.5mg/d, p<0.001), and DK(+) compared to DK(-) groups (291.4 mg/d versus 251.9 mg/d, p=0.001). The time until dopamine agonist (DA) initiation was longer in WO(+)/DK(+) groups (p<0.001). WO (p<0.001) and DK (p=0.002) were more common in patients with H&Y stages 3+4. UPDRS scores were higher in WO(+) and DK(+) patients (p<0.001 and p=0.027). CONCLUSION: Our study showed that the development of motor complications was associated with early onset PD, longer disease duration, advanced disease, higher initial LD dose, longer LD use, and late DA initiation, but not with the timing of LD initiation. SN - 0303-8467 UR - https://www.unboundmedicine.com/medline/citation/16564615/A_hospital_based_study:_risk_factors_in_development_of_motor_complications_in_555_Parkinson's_patients_on_levodopa_therapy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0303-8467(06)00015-1 DB - PRIME DP - Unbound Medicine ER -